Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Recommendation of “Hold” by Brokerages

Medpace Holdings, Inc. (NASDAQ:MEDP) has been assigned a consensus rating of “Hold” from the seventeen analysts that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $487.1818.

A number of research analysts recently commented on the stock. Robert W. Baird set a $613.00 price objective on shares of Medpace in a research report on Friday, October 24th. Rothschild & Co Redburn cut shares of Medpace from a “buy” rating to a “neutral” rating and boosted their price target for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Barclays increased their price objective on Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a report on Friday, October 24th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Finally, Mizuho upped their target price on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th.

Insider Buying and Selling

In related news, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 387,925 shares of company stock worth $233,386,647. Insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

Several hedge funds have recently bought and sold shares of MEDP. Quent Capital LLC acquired a new stake in shares of Medpace in the third quarter worth about $25,000. Optiver Holding B.V. bought a new position in shares of Medpace in the 3rd quarter valued at approximately $27,000. Geneos Wealth Management Inc. boosted its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Brooklyn Investment Group grew its holdings in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after purchasing an additional 71 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Medpace in the third quarter valued at approximately $35,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Trading Down 0.9%

Shares of MEDP stock opened at $544.08 on Wednesday. The company has a market capitalization of $15.33 billion, a price-to-earnings ratio of 38.05, a P/E/G ratio of 2.06 and a beta of 1.43. Medpace has a 1-year low of $250.05 and a 1-year high of $626.26. The stock’s fifty day simple moving average is $569.47 and its 200-day simple moving average is $458.38.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same period last year, the company posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts predict that Medpace will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.